In a report released on March 9, 2017, a National Academies of Sciences, Engineering, and Medicine committee concluded that the bioeconomy is growing rapidly and the US regulatory system needs to provide a balanced approach to the many competing interests that will arise in the face of the expansion. The Committee also noted that regulators should be prepared for a broad array of new types of biotechnology products.

The report by the Committee on Future Biotechnology Products and Opportunities to Enhance the Capabilities of the Biotechnology Regulatory System is part of a larger effort initiated in July 2015 by the White House Office of Science and Technology Policy to clarify the roles of the agencies with primary responsibility for regulating products of biotechnology, to develop a long-term strategy to ensure that the regulatory system is prepared for future biotechnology products, and to commission an expert analysis of the future landscape of biotechnology products. The goal of the work is to increase public confidence in the regulatory system and to prevent unnecessary barriers to future innovation and competitiveness.

The Committee was tasked with undertaking the external, independent analysis of the future landscape of biotechnology products. The Committees newly-issued report follows the release of policy documents by FDA and USDA and the 2017 Update to the Coordinated Framework for the Regulation of Biotechnology, issued by OSTP earlier this year.

The Committee was charged with answering the following horizon-scanning questions: 1) What will the likely future products of biotechnology be over the next 5 10 years? and 2) What scientific capabilities, tools, and/or expertise may be needed by the regulatory agencies to ensure they make efficient and sound evaluations of the likely future products of biotechnology? The Committee spent several months gathering information from a number of sources, including hearing from 74 speakers over the course of three in-person meetings and eight webinars, and responses from a dozen federal agencies. The Committee also solicited statements and written comments from the public.

The Committee identified a number of broad themes regarding future opportunities for enhancing the biotechnology regulatory system to best accommodate these new products:

Based on these conclusions, the Committee outlined three overall recommendations to enhance the capabilities of the biotechnology regulatory system in order to prepare for future biotechnology products, focusing primarily on the science-readiness of the federal regulators tasked under the Coordinated Framework with assessing new products of biotechnology:

The Committees identification of themes and recommendations is timely, given that federal agencies like USDA and FDA are currently seeking stakeholder feedback on those agencies proposed approaches to regulating products of genome editing.

See the original post:
Future of Biotech: National Academies Committee Report Scans the Horizon - Lexology (registration)

Sam Konduros(Photo: Provided)

Sam Konduros, a former executive director of Greenville Health Systems Research Development Corporation, was named on Monday as the new president and CEO of the S.C. Biotechnology Industry Organization.

SCBIO is a statewide, non-for-profit that represents and organizes innovators in medicine, medical devices and biomaterials.

Konduros is a currently a member of the SCBIO Board of Directors.

I greatlyappreciate the SCBIO boardspassion forservingand advancing South Carolinas rapidly growing life sciences community and industry sector, and for their vote of confidence in my leadership capabilities for the organization going forward, Konduros said in a statement.

Architecture and design firm adds new hire to Greenville office

Verizon looks to fill 100 positions at new telesales center in Greenville

Konduros, a business leader and biomedical and economic development consultant, is the founder of SK Strategies LLC, launched in 2004, and has led a number of state economic development efforts.

He was the founding president and CEO of theUpstate S.C. Alliance, and is a former chairman for the Greenville Chamber of Commerce and a former committee member of the S.C. Chamber of Commerce.

Konduros has a law degree from the University of South Carolina and an undergraduate degree from Clemson University. He is alsoa graduate of the Economic Development Institute at the University of Oklahoma.

Sams strengths in knowing the biotech sector and his deep experience in business and economic development were compelling, Erin Ford, chair of SCBIO, said in a statement. The board was won over by his vision for the growth of SCBIO.

Read or Share this story: http://grnol.co/2mJTIWt

Original post:
Sam Konduros named president and CEO of S.C. Biotechnology ... - Greenville News

Active investors may be taking a second look at shares of Puma Biotechnology, Inc. (NASDAQ:PBYI). Checking in on some levels, the six month price index is currently at 0.69011. The six month price index is measured by dividing the current share price by the share price six months ago. A ratio above one indicates an increase in the stock price over the six month time frame. A ratio under one signals that the price has lowered over that same time frame.

We can also take a look at some stock volatility data on shares of Puma Biotechnology, Inc. (NASDAQ:PBYI). The 12 month volatility is currently 89.457300. The 6 month volatility is noted at 86.055100, and the 3 month is recorded at 77.682900. When following the volatility of a stock, investors may be challenged with trying to decipher the correct combination of risk-reward to help maximize returns. As with any strategy, it is important to carefully consider risk and other market factors that might be in play when examining stock volatility levels.

Investors may be looking at the Piotroski F-Score when doing value analysis. The F-Score was developed to help find company stocks that have solid fundamentals, and to separate out weaker companies. Piotroskis F-Score uses nine tests based on company financial statements. Puma Biotechnology, Inc. (NASDAQ:PBYI) currently has a Piotroski F-Score of 2. One point is given for piece of criteria that is met. Typically, a stock with a high score of 8 or 9 would be seen as strong, and a stock scoring on the lower end between 0 and 2 would be viewed as weaker.

Shifting gears, Puma Biotechnology, Inc. (NASDAQ:PBYI) has an FCF quality score of -6.273255. The free quality score helps estimate the stability of free cash flow. FCF quality is calculated as the 12 ltm cash flow per share over the average of the cash flow numbers. When reviewing this score, it is generally thought that the lower the ratio, the better. Presently, Puma Biotechnology, Inc. has an FCF score of 0.359983. The FCF score is determined by merging free cash flow stability with free cash flow growth. In general, a higher FCF score value would represent high free cash flow growth. Monitoring FCF information may help provide some excellent insight on the financial health of a specific company.

Investors might want to take a look at shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) from a different angle. Lets take a peek at the current Q.i. (Liquidity) Value. Puma Biotechnology, Inc. (NASDAQ:PBYI) has a Q.i. value of 82.00000. This value ranks stocks using EBITDA yield, FCF yield, earnings yield and liquidity ratios. The Q.i. value may help identify companies that are undervalued. A larger value would indicate low turnover and a higher chance of shares being priced incorrectly. A lower value may show larger traded value meaning more sell-side analysts may track the company leading to a lesser chance that shares are priced improperly.

By DR Staff Writer

See original here:
Investors are Watching Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - Davidson Register

Insider Trading at Puma Biotechnology Inc? Sports Perspectives Puma Biotechnology logo Puma Biotechnology Inc (NYSE:PBYI) insider Robert Charnas sold 3,008 shares of the firm's stock in a transaction that occurred on Wednesday, February 1st. The stock was sold at an average price of $31.83, for a total transaction ... Puma Biotechnology Inc Risk Points versus Health CareCML News The Puma Biotechnology Inc (PBYI) Insider Sells $95744.64 in StockDailyQuint Robert Charnas Sells 3008 Shares of Puma Biotechnology Inc (PBYI) StockCommunity Financial News Fiscal Standard all 8 news articles »

Read the original post:
Insider Trading at Puma Biotechnology Inc? - Sports Perspectives

iShares Nasdaq Biotechnology Index Fund (IBB) traded higher in the last at $284.75, gaining 0.19 points or 0.07%. From the data available, it can be said that the stock did not make an impact in the money flow department with the net figure coming to be $(-2.92) million. The composite uptick value of $19.32 million was eclipsed by the accrued downtick value of $22.25 million, thereby ensuring the up/down ratio of 0.87. For the week, the shares have posted returns of 0.6%.

iShares Nasdaq Biotechnology is having a Relative Strength Index of 61.82 which indicates the stock is not yet over sold or over bought based on the technical indicators.

Based on the Stock Research reports from financial advisors, there are Analysts recommending as a Strong Buy, and Analysts recommending as a Moderate Buy. Investors should also note that Stock brokerage firms are recommending to Hold the stock for short term. Stock Research experts are recommending to Sell based on the growth. There are Analysts recommending as a Strong Sell.

iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) witnessed a decline in the market cap on Friday as its shares dropped 0.07% or 0.19 points. After the session commenced at $284.48, the stock reached the higher end at $285.88 while it hit a low of $283.55. With the volume soaring to 764,100 shares, the last trade was called at $284.37. The company has a 52-week high of $301.8. The company has a market cap of $8,332 million and there are 29,300,000 shares in outstanding. The 52-week low of the share price is $240.3.

The ISHARES NASDAQ BIOTECHNOLOGY INDEX FUND seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of companies primarily engaged in the biotechnology industry, as represented by the NASDAQ Biotechnology Index.

Read more from the original source:
Large Outflow of Money Witnessed in iShares Nasdaq ... - Highland Mirror

Commentary | Feb. 6, 2017

Should Christians face unethical uses of biotechnology with despair and resignation or with hope and determination?

Ive spent the last decade writing and speaking about the remarkable and terrifying world of biotechnology from a Catholic perspective. Many times Ive felt like Frodo Baggins at the gates of Mordor, looking upon Mt. Doom with despair and dread.

Ive never felt this more acutely than in the past few months. A series of recent headlines have renewed my sense of hopelessness in the face of the never-ending assault on the dignity of human life by modern biotechnology.

The gloom began to settle when it was revealed that a Swedish scientist is editing the DNA of healthy human embryos.Fredrik Lanner,a developmental biologist, is using a new gene-editing technique called CRISPR to disable some genes in healthy human embryos to see how those genes affect development. He and his team are intentionally modifyingotherwise healthy IVFembryos so they cannot develop properly.

Anin-depth story byNPRreveals that while the reporter was observing thegeneticmanipulation of five donated IVF embryos, one didnt survive the thawing process and one perished after being injected with the experimental gene-editing tool. Of the three who survived, one continued to divide, but not for long.All of the embryos were to be destroyedbefore they are 15 days old,as the law in Sweden dictates. Lanner insists that his research is critical to understanding human development, which, in turn, will shed light on infertility and disease.

Lanners work makes many ethicists and scientists extremely nervous. Jennifer Doudna, the co-inventor of CRISPR, along with other heavy-hitting scientists,havecalled for a voluntary moratorium on any editing of human embryosfor fear that it will lead to the creation of genetically modified children. Marcy Darnovsky, of the left-leaning Center for Genetics and Society, explains why she and her group havebeen so vocal in their opposition to the modification of human embryos. She told NPR: The production of genetically modified human embryos is actually quite dangerous. ... When youre editing the genes of human embryos, that means youre changing the genes of every cell in the bodies of every offspring, every future generation of that human being. So these are permanent and probably irreversible changes that we just dont know what they would mean.

Then came the revelation that a U.S. doctor traveled to Mexico to create the first baby intentionally engineered to have three genetic parents. This technique, misnamed mitochondrial replacement or MR, seeks to eliminate the transmission of genetic disease through the mitochondria.Mitochondria are small but abundant organellesoutside the nucleusinthe cytoplasmof our cells that make energy. They have their own DNA called mtDNA. We inherit our mtDNA solely from our mothers. A woman who carries a deleterious mutation in her mtDNA cannot help but pass that on to her offspring.

There are various MR techniques that replace the mitochondria of a woman with mitochondrial disease with the mitochondria of a donor femalein the IVF process.Essentially, MR creates a genetically alteredembryo with the genetic material from three people, one man and two women.

MR had only undergone limited study in primates before getting approval in the United Kingdom for use in fertility clinics to make babies. Little is known about the complexcommunication between the DNA in the nucleus and the DNA in the mitochondria,and so there is little data on the effects ofa mismatch between the nuclear DNA and mtDNA.

Alsoin all MR, its the nucleus thats being moved from cell to cell, not the mitochondria which is why mitochondrial replacement is such a misnomer.This makes MR acousin to cloning, which also transplants the nucleus of one cell into anotherto make a new organism. MR brings with it many of the same risks.Scientists are concerned about the health of the resulting children.

In anopen letterto the U.K. Parliament, Dr. Paul Knoepfler, a vocal American stem-cell researcher, warned: Even if, hypothetically, this technology might help avoid some people from having mitochondrial disorders (and thats a big if), the bottom line is that there is an equal or arguably greater chance that it will tragically produce very ill or deceased babies.

MRis also a germ-line genetic modification, which means that any girl born with this technique will pass her genetic modification on to her children.

A recent review in Nature reveals that MR leaves a tiny percentage of mutant mitochondria behind, and sometimes the mutant mitochondria rapidly divide and overtake the healthy mitochondria. Shoukhrat Mitalipov, head of the Center for Embryonic Cell and Gene Therapy at the Oregon Health and Science University, reported a 15% failure rate where mitochondrial defects returned. Mitalipov told NPR, That original, maternal mitochondrial DNA took over, and it was pretty drastic. There was less than 1% of the original maternal mitochondrial DNA present after replacement with donor DNA and before fertilization, and yet it took over the whole cell later. University of California San Francisco professor Patrick OFarrell suggests that mutant mitochondria can resurge at any time in a developing three-parent child or even resurface in future generations.

For all these reasons, MR is not yet approved by the FDA in the United States,and may never be.So, when a Jordanian woman with mitochondrial disease wanted to have a child using MR, John Zhang, from the New Hope Fertility Center in New York City, had to perform the procedure in Mexico. He created five embryos,and, according toNewScientist.com,only one developed normally. That child is now 9 months old.

Zhang went to Mexico because, he said, there are no rules, and yet he insists he did the safe and ethical thingin the absence of any medical or ethical oversight. In an ironic twist, the couple is Muslim and so chose the MR technique that wouldnt destroy existing embryos.But it was clear that only male embryos would be transferred for gestation, because boys cant pass on the genetic modification. What happened to the other four embryos, however? Were they destroyed,discarded or frozen? If they were females, would they have been destroyed anyway to make sure they couldnt pass on any ill effects?

Darnovskycalledthis rogue experimentationand added, No researcher or doctor has the right to flout agreed-upon rules and make up their own. This is an irresponsible and unethical act.

Knoepflerrespondedto the news by remindingus that this is a living human experiment that is going to unfold over years and decades. It is also worth noting that this child is a genetically modified human being as a result of this technique.

Of course, these are happenings to despair of not only because of the sheer disregard for the sanctity of individual human lives, but because of the breakneck speed at which scientists are kicking ethical lines farther and farther down the road like a tin can. All the while, they insist that its for the good of humanity. I wonder: How can wetreatindividual members of the human species so callously and then, at the same time, say its for the good of the whole human race?

I fear there is no line we wont cross;no ethical boundary wewonttear down in the name of science.

On a daily basis, Im surrounded by science and scientists. Often, their response to this madness is that its going to happen anyway, and theres no way to stop it, which implies we must go along to get along all in the name of progress.

If I am Frodo, then they and the rest of society are Saruman giving in to the despair and making a deal with Sauron.In the film version of The Lord of the Rings, Saruman says to Gandalf: Against the power of Mordor there can be no victory. We must join with him, Gandalf. We must join with Sauron. It would be wise, my friend.

Gandalf replies, Tell me, friend, when did Saruman the Wise abandon reason for madness?

Indeed. When did science abandon reason for madness, ethics for recklessness?

So what shall we do? If wesuccumb to despair, we become like Saruman.

We always have prayer. Its time toadd human embryonic research and germ-line human genetic engineering to our list of life issues that we pray about.It doesnt matter whether we understand the finer points of the science or not.Praying for an end to abortion andassisted suicide is nolongerenough.

In addition to prayer, there are other things we can do. The first is to vote pro-life at every level of government, from city council to state assemblymen. Being pro-life isnt just about abortion, however. Its about protecting the sanctity of life from the beginning to the end. Pro-life legislators, even if they cannot overturn Roe v. Wade, can effect local and state laws and steer funding away from unethical research.

Secondly, we must fight for conscience rights for medical professionals. I envision a not-so-far-off world wheredoctorsare forced into making genetically engineered embryos and bringing these children to term simply because parents claim its their reproductive right to have the children of their design. Without conscience rights, unethical experimentation on the next generation will be rampant and unchecked.

We must, however, always have hope. Whenstaring downthe juggernaut that is modern biotechnology, I always remember Frodo Baggins.When he was faced with the seemingly impossible task of taking the One Ring to Mordor, instead of shying away because it was too hard, he said: I will take the Ring, though I do not know the way.

Rebecca Tayloris a

clinical laboratory specialist in molecular biology.

She writes about bioethics on her blog,Mary Meets Dolly.

Go here to read the rest:
Immoral Uses of Biotechnology Even With Good Intentions Are Evil - National Catholic Register

Dublin-based Malin invested in US biotechnology company Artizan Biosciences via a funding round

Irish-based life sciences company Malin said on Monday it has acquired a 32 per cent shareholding of US biotechnology company Artizan Biosciences.

Dublin-based Malin, which has invested more than 300 million in life sciences companies since it was established in early 2015, invested in Artizan via a founding equity round alongside Hatteras Venture Partners, a venture capital firm with which Malin has a strategic partnership.

Artizan is a newly created biotechnology company headquartered in Durham, North Carolina, with labs in New Haven, Connecticut, that was founded to address diseases involving the human intestinal microbiota.

It was spun out of Yale University and established as a standalone business in 2016. Its founders include Prof Richard Flavell, Noah Palm, PhD, and Marcel de Zoete, PhD, from Yale University.

Artizan, which aims to be a leader in the microbiota-driven inflammatory diseases space, has developed a capability of distinguishing certain pathogenic bacteria from the remainder of the intestinal microbiota.

The ability to target these specific bacteria could lead to treatment options for any number of digestive disorders as well as other diseases including obesity, autoimmune disease and a wide variety of skin, lung and central nervous system diseases.

Artizans proposed approach is disruptive to current treatment and would offer new and novel therapeutic options for patients suffering from a broad array of inflammatory disorders, Adrian Howd, chief investment officer of Malin, said.

Last month Malin acquired a 33 per cent shareholding of Wren Therapeutics, a newly created biopharmaceutical company based in Cambridge, England. It was set up by a number of former Elan executives in 2015.

See the original post:
Malin stakes 32% take in US biotechnology company Artizan - Irish Times

More Volatility Ahead for Biotechnology Sector Wall Street Journal (blog) After underperforming the S&P 500 over the past six months, the biotechnology sector is poised for more volatility ahead. The group drew plenty of attention on the campaign trail as both and Democratic candidate criticized the high prices for drugs ...

Read this article:
More Volatility Ahead for Biotechnology Sector - Wall Street Journal (blog)

Considering a Masters in Biotechnology Program or reviewing options for Masters Degrees in Biotechnology? A Masters in Biotechnology can openupexciting

Biotechnology is a challenging field that can involve a number of facets of both science and business or law. Many biotechnology master's degree programs focus on aspects of biology, cell biology, chemistry, or biological or chemical engineering. In general, biotechnology degrees involve research whether they are at a Masters or PhD level.

Scientific understanding is rapidly evolving, particularly in areas of cellular and molecular systems. Biotechnology master's students can therefore enjoy rich study opportunities particularly in fields such as genetic engineering, the Human Genome project, the production of new medicinal products, and research into the relationship between genetic malfunction and the origin of disease. These are just a few of the many areas that biotechnology students have the opportunity to explore today.

Another focus of biotechnology masters programs may be to equip students with the combination of science and business knowledge they need to help produce products and move them toward production. Today's complex business environment and government regulations require many steps and people with the ability to both understand and help produce new scientific technologies as well as get them approved and be able to market them.

Master degrees in biotechnology might prepare students to pursue careers in a variety of industries. While many students go on to further research or academic positions, there may also be some demand for biotechnologists outside of academia, both in the government and private sectors. Biotechnologists might pursue careers in anything from research to applied science and manufacturing. Those with specializations in business aspects of biotechnology may be qualified to pursue management positions within organizations attempting to produce and market new biotechnology.

Go here to see the original:
Masters in Biotechnology Programs and Degrees in Biotechnology

A Master of Science or MSc is a graduate degree with a focus in science, medicine, or engineering. The MSc in Biotechnology combines two of these disciplines, focusing on biology and chemistry along with principles of design and engineering.

Exactly what is an MSc in Biotechnology? The field of biotechnology uses living organisms to generate controlled processes or even final products. Students pursuing this degree learn about a wide range of topics. On the biological side, focuses may include genetics, microbiology, cellular biology, and biochemistry. On the design and engineering side, students may learn about subjects such as process design and genetic engineering. Some programs also allow students to focus on a subdiscipline, such as the role of bioengineering and bioscience in healthcare or food production.

This degree program prepares students for biotechnology careers by encompassing a broad range of subjects that many degree programs do not. Besides providing students with necessary knowledge, the degree coursework fosters problem solving and critical thinking skills that prepare students to take on various design and engineering challenges. Additionally, earning the degree can improve likelihood of employment as science and engineering employers often prefer candidates with graduate degrees.

The cost of a masters degree program can vary significantly, depending on the educational institution, region, and country. Anyone who is considering pursuing a Master of Science should compare various options to find a program that is financially reasonable.

Someone who has earned the MSc in Biotechnology can work in research or development in a variety of bioengineering fields. These include pharmaceutical or medical design, genetic engineering, biofuel production, and industrial biotechnology systems. Potential employers include universities, research institutions, and private companies.

Today, even advanced Master of Science degrees can be earned online. Online degrees can be a convenient option for people with busy schedules or limited access to in-person education. The online application process is streamlined, and learning about your potential options is easy. Search for your program below and contact directly the admissions office of the school of your choice by filling in the lead form.

See the article here:
Best Masters of Science (MScs) in Biotechnology 2017

Journal of Biotechnology & Biomaterials is a peer reviewed journal which publishes high quality articles reporting original research, review, commentary, opinion, rapid communication, case report etc. on all aspects of Biotechnology and Biomaterials. Content areas include Plant/Animal/Microbial Biotechnology, Applied Biotechnology, Red/Medical Biotechnology, Green/Agricultural Biotechnology, Environmental Biotechnology, Blue/Marine Biotechnology, White/Industrial Biotechnology, Food Biotechnology, Orthopedic and Dental Biomaterials, Cardiovascular Biomaterials, Ophthalmologic Biomaterials, Bioelectrodes and Biosensors, Burn Dressings and Skin Substitutes, Sutures, Drug Delivery Systems etc. This Biotechnology Journal with highest impact factor offers Open Access option to meet the needs of authors and maximize article visibility.

The journal is an academic journal providing an opportunity to researchers and scientists to explore the advanced and latest research developments in the use of living organisms and bioprocesses in engineering, technology and medicine. The Journal of Biotechnology and Biomaterials is of highest standards in terms of quality and provides a collaborative open access platform to the scientists throughout the world in the field of Biotechnology and Biomaterials. Journal of Biotechnology and Biomaterials is a scholarly Open Access journal and aims to publish the most complete and reliable source of information on the advanced and very latest research topics.

The journal is using the Editorial Manager System for quality in the peer-review process. Editorial Manager System is an online submission and review system, where authors can submit manuscripts and track their progress. Reviewers can download manuscripts and submit their opinions. Editors can manage the whole submission, review, revise & publish process. Publishers can see what manuscripts are in the pipeline awaiting publication.

The Journal assures a 21 days rapid review process with international peer-review standards and with quality reviewers. E-mail is sent automatically to concerned persons when significant events occur. After publishing, articles are freely available through online without any restrictions or any other subscriptions to researchers worldwide.

Applied Biotechnology is gives the major opportunity to study science on the edge of technology, innovation and even science itself. Applied Microbiology and Biotechnology focusses on prokaryotic or eukaryotic cells, relevant enzymes and proteins; applied genetics and molecular biotechnology; genomics and proteomics; applied microbial and cell physiology; environmental biotechnology; process and products and more.

Related Journals of Applied Biotechnology

Current Opinion in Biotechnology, Biotechnology Advances, Biotechnology for Biofuels, Journal of Bioprocessing & Biotechniques, Journal of Bioterrorism & Biodefense, Molecular Biology, Biology and Medicine, Crop Breeding and Applied Biotechnology, Applied Mycology and Biotechnology, Asian Biotechnology and Development Review, Biotechnology applications Journals, Journal of Applied Biomaterials & Fundamental Materials.

Biomaterials are commonly used in various medical devices and systems such as drug delivery systems, hybrid organs, tissue cultures, synthetic skin, synthetic blood vessels, artificial hearts, screws, plates, cardiac pacemakers, wires and pins for bone treatments, total artificial joint implants, skull reconstruction, and dental and maxillofacial applications. Among various applications, the application of biomaterials in cardiovascular system is most significant. The use of cardiovascular biomaterials (CB) is subjected to its blood compatibility and its integration with the surrounding environment where it is implanted.

Related Journals of Cardiovascular biomaterials

Journal of Biomimetics Biomaterials and Tissue Engineering, Journal of Advanced Chemical Engineering, Journal of Bioprocessing & Biotechniques, Journal of Biomaterials Science, Polymer Edition, Journal of Biomaterials Applications, Trends in Biomaterials and Artificial Organs, International Journal of Biomaterials and Journal of Biomaterials and Tissue Engineering, Cardiovascular biomaterials Journals.

Biomaterials are used daily in surgery, dental applications and drug delivery. Biomaterial implant is a construct with impregnated pharmaceutical products which can be placed into the body, that permits the prolonged release of a drug over an extended period of time. A biomaterial may also be an autograft, allograft or xenograft used as a transplant material.

Related journals of Biomaterial implants

Advanced Functional Materials, Biomaterials, Advanced healthcare materials, Journal of Biomimetics Biomaterials and Tissue Engineering, Journal of Molecular and Genetic Medicine, Journal of Phylogenetics & Evolutionary Biology, Clinical Oral Implants Research, International Journal of Oral and Maxillofacial Implants, Journal of Long-Term Effects of Medical Implants and Cochlear Implants International, Biomaterials Journals, Biomaterial implants Journals.

Animal Biotechnology covers the identification and manipulation of genes and their products, stressing applications in domesticated animals. Animals are used in many ways in biotechnology. Biotechnology provides new tools for improving human health and animal health and welfare and increasing livestock productivity. Biotechnology improves the food we eat - meat, milk and eggs. Biotechnology can improve an animals impact on the environment.

Related Journals of Animal biotechnology

Journal of Bioprocessing & Biotechniques, Journal of Molecular and Genetic Medicine, Biology and Medicine, Journal of Advanced Chemical Engineering, Animal Biotechnology, African Journal of Biotechnology, Current Pharmaceutical Biotechnology, Critical Reviews in Biotechnology and Reviews in Environmental Science and Biotechnology, Asian Journal of Microbiology Biotechnology and Environmental Sciences.

A biomaterial is any surface, matter, or construct that interacts with biological systems. The biomaterial science is the study of biomaterials. Biomaterials science encloses elements of medicine, biology, chemistry, tissue engineering and materials science. Biomaterials derived from either nature or synthesized in the laboratory using a different typrs of chemicals utilizing metallic components, polymers, ceramics or composite materials. They are oftenly used for a medical application.

Related Journals of Biomaterials

Biosensors and Bioelectronics, Journal of Bioactive and Compatible Polymers, Journal of Tissue Engineering, Journal of Biomimetics Biomaterials and Tissue Engineering, Journal of Bioterrorism & Biodefense, Fermentation Technology, Journal of Phylogenetics & Evolutionary Biology, International Journal of Nano and Biomaterials, Journal of Biomimetics, Biomaterials, and Tissue Engineering, Journal of Applied Biomaterials and Fundamental Materials, Journal of Biomaterials and Tissue Engineering and International Journal of Biomaterials.

Nanobiotechnology, nanobiology and bionanotechnology are terms that refer to the intersection of nanotechnology and biology. Bionanotechnology and nanobiotechnology serve as blanket terms for various related technologies. This discipline helps to indicate the merger of biological research with various fields of nanotechnology. Concepts enhanced through nanobiology are nanodevices, nanoparticles, and nanoscale phenomena. Nanotechnology uses biological systems as the biological inspirations.

Related Journals of Nano biotechnology

Biopolymers, Journal of the Mechanical Behavior of Biomedical Materials, Journal of Tissue Engineering and Regenerative Medicine, Journal of Bioprocessing & Biotechniques, Journal of Bioterrorism & Biodefense, Journal of Molecular and Genetic Medicine, Journal of Advanced Chemical Engineering, Journal of Nanobiotechnology, Artificial Cells, Nanomedicine and Biotechnology, IET Nanobiotechnology and Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, Australian journal of biotechnology, International Journal of Nano & Biomaterials, Nano biotechnology Journals.

Biocatalysis are used as natural catalysts, like protein enzymes, to perform chemical transformations on organic compounds. Both enzymes that have been more or less isolated and enzymes still residing inside living cells are employed for this task. Since biocatalysis deals with enzymes and microorganisms, it is historically classified separately from "homogeneous catalysis" and "heterogeneous catalysis". However, biocatalysis is simply a heterogeneous catalysis.

Related Journals of Biocatalysis

Biology and Medicine, Fermentation Technology, Journal of Advanced Chemical Engineering, Biocatalysis and Biotransformation and Biocatalysis and Agricultural Biotechnology.

Agricultural biotechnology is a collection of scientific techniques used to improve plants, animals and microorganisms. Based on an structure and characteristics of DNA, scientists have developed solutions to increase agricultural productivity. Scientists have learned how to move genes from one organism to another. This has been called genetic modification (GM), genetic engineering (GE) or genetic improvement (GI). Regardless of the name, the process allows the transfer of useful characteristics (such as resistance to a disease) into a plant, animal or microorganism by inserting genes from another organism.

Related Journals of Agricultural biotechnology

Journal of Phylogenetics & Evolutionary Biology, Journal of Molecular and Genetic Medicine, Molecular Biology, Journal of Bioprocessing & Biotechniques, Biocatalysis and Agricultural Biotechnology and Chinese Journal of Agricultural Biotechnology, Plant Biotechnology Journal, Plant Biotechnology Journals.

A biomolecule is any molecule which is present in living organisms, entails large macromolecules like proteins, lipids, polysaccharides, and nucleic acids, as well as small molecules include primary metabolites, secondary metabolites, and natural products. A common name for this class of material is biological materials. Nucleosides are molecules formed by attaching a nucleobase to a ribose or deoxyribose ring. Nucleosides can be phosphorylated by specific kinases in the cell, producing nucleotides.

Related Journals of Bio-molecules

Molecular Biology, Biology and Medicine, Journal of Molecular and Genetic Medicine, Journal of Phylogenetics & Evolutionary Biology, Biomolecules and Therapeutics, Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology, Asia-Pacific Journal of Molecular Biology and Biotechnology, Bio-molecules Journals.

In developing countries, application of biotechnology to food processing is an issue of argument and discussions for a long time. Biotechnological study focuse development and improvement of customary fermentation processes. The application of Biotechnology to solve the environmental problems in the environment and in the ecosystems is called Environmental Biotechnology. It is applied and used to study the natural environment.

Related Journals of Biotechnology applications

NatureBiotechnology, Trends inBiotechnology, MetabolicEngineering, Journal of Bioprocessing & Biotechniques,Journal of Phylogenetics & Evolutionary Biology, Journal ofAdvanced Chemical Engineering, Applied Microbiology andBiotechnology, Applied Biochemistry and Biotechnology - PartA Enzyme Engineering and Biotechnology, Biotechnology and AppliedBiochemistry, Applied Biotechnology Journals, Applied Microbiologyand Biotechnology, Systems and Synthetic Biology and IET SyntheticBiology.

Industrial or white biotechnology uses enzymes and micro-organisms to make biobased products in sectors like chemicals, food and feed, detergents, paper and pulp, textiles and bioenergy (such as biofuels or biogas). It uses renewable raw materials and is one of the most promising, newest approaches towards lowering greenhouse gas emissions. Industrial biotechnology application has been proven to make significant contributions towards mitigating the impacts of climate change in these and other sectors.

Related Journals of White/industrial biotechnology

Critical Reviews in Biotechnology, Biotechnology and Bioengineering, Microbial Biotechnology, Journal of Bioprocessing & Biotechniques, Journal of Bioterrorism & Biodefense, Fermentation Technology, Molecular Biology, Journal of Phylogenetics & Evolutionary Biology, Journal of Molecular and Genetic Medicine, Chemical Sciences Journal, Industrial Biotechnology and Journal of Industrial Microbiology and Biotechnology, White/industrial biotechnology Journals.

Go here to read the rest:
Biotechnology Journals | Open Access - omicsonline.org

Environmental biotechnology is biotechnology that is applied to and used to study the natural environment. Environmental biotechnology could also imply that one try to harness biological process for commercial uses and exploitation. The International Society for Environmental Biotechnology defines environmental biotechnology as "the development, use and regulation of biological systems for remediation of contaminated environments (land, air, water), and for environment-friendly processes (green manufacturing technologies and sustainable development)".[1]

Environmental biotechnology can simply be described as "the optimal use of nature, in the form of plants, animals, bacteria, fungi and algae, to produce renewable energy, food and nutrients in a synergistic integrated cycle of profit making processes where the waste of each process becomes the feedstock for another process".[2]

Science through the IAASTD has called for the advancement of small-scale agro-ecological farming systems and technology in order to achieve food security, climate change mitigation, climate change adaptation and the realisation of the Millennium Development Goals. Environmental biotechnology has been shown to play a significant roll in agroecology in the form of zero waste agriculture and most significantly through the operation of over 15 million biogas digesters worldwide.

Consider an environment in which pollution of a particular type is maximum. Let us consider the effluents of a starch industry which has mixed up with a local water body like a lake or pond. We find huge deposits of starch which are not so easily taken up for degradation by micro-organisms except for a few exemptions. we isolate a few micro-organisms from the polluted site and scan for any significant changes in their genome like mutations or evolutions. The modified genes are then identified. This is done because, the isolate would have adapted itself to degrade/utilize the starch better than other microbes of the same genus. Thus, the resultant genes are cloned onto industrially significant micro-organisms and are used for more economically significant processes like in pharmaceutical industry, fermentations...etc.

Similar situations can be elucitated like in the case of oil spills in the oceans which require cleanup, microbes isolated from oil rich environments like oil wells, oil transfer pipelines...etc. have been found having the potential to degrade oil or use it as an energy source. Thus they serve as a remedy to oil spills.

Still another elucidation would be in the case of microbes isolated from pesticide rich soils These would be capable of utilizing the pesticides as energy source and hence when mixed along with bio-fertilizers, would serve as excellent insurance against increased pesticide-toxicity levels in agricultural platform.

But the counter argument would be that whether these newly introduced microorganisms would create an imbalance in the environment concerned.The mutual harmony in which the organisms in that particular environment existed may have to face alteration and we should be extremely careful so as to not disturb the mutual relationships already existing in the environment of both the benefits and the disadvantages would pave way for an improvised version of environmental biotechnology. After all it is the environment that we strive to protect.

Humans have been manipulating genetic material for centuries. Although many benefits are provided by these manipulations, there can also be unexpected, negative health and environmental outcomes. Environmental biotechnology, then, is all about the balance between the applications that provide for these and the implications of manipulating genetic material.[3] Textbooks address both the applications and implications. Environmental engineering texts addressing sewage treatment and biological principles are often now considered to be environmental biotechnology texts. These generally address the applications of biotechnologies, whereas the implications of these technologies are less often addressed; usually in books concerned with potential impacts and even catastrophic events.

Read the original post:
Environmental biotechnology - Wikipedia

Session & Tracks

Track 1:Molecular Biotechnology

Molecular biotechnology is the use of laboratory techniques to study and modify nucleic acids and proteins for applications in areas such as human and animal health, agriculture, and the environment.Molecular biotechnologyresults from the convergence of many areas of research, such as molecular biology, microbiology,biochemistry, immunology, genetics, and cell biology. It is an exciting field fueled by the ability to transfer genetic information between organisms with the goal of understanding important biological processes or creating a useful product.

Related Conferences

11th World Congress onBiotechnology and Biotech IndustriesMeet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA; GlobalBiotechnology Congress2016, May 11th-14th 2016, Boston, MA, USA;BIO Investor Forum, October 20-21, 2015, San Francisco, USA;BIO Latin America Conference, October 14-16, 2015, Rio de Janeiro, Brazil;Bio Pharm America 20158th Annual International Partnering Conference, September 15-17, 2015, Boston, MA, USA.

Track 2:Environmental Biotechnology

The biotechnology is applied and used to study the natural environment. Environmental biotechnology could also imply that one try to harness biological process for commercial uses and exploitation. It is "the development, use and regulation of biological systems for remediation of contaminated environment and forenvironment-friendly processes(green manufacturing technologies and sustainable development). Environmental biotechnology can simply be described as "the optimal use of nature, in the form of plants, animals, bacteria, fungi and algae, to producerenewable energy, food and nutrients in a synergistic integrated cycle of profit making processes where the waste of each process becomes the feedstock for another process".

Related Conferences

11th World Congress onBiotechnology and Biotech IndustriesMeet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA; GlobalBiotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & BiotechPatent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands

Track 3:Animal Biotechnology

It improves the food we eat - meat, milk and eggs. Biotechnology can improve an animals impact on the environment. Animalbiotechnologyis the use of science and engineering to modify living organisms. The goal is to make products, to improve animals and to developmicroorganismsfor specific agricultural uses. It enhances the ability to detect, treat and prevent diseases, include creating transgenic animals (animals with one or more genes introduced by human intervention), using gene knock out technology to make animals with a specific inactivated gene and producing nearly identical animals by somatic cell nuclear transfer (or cloning).

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA;Global Biotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & BiotechPatent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkers in Diagnostics, Oct 07-08, 2015 Berlin, Germany, DEU.

Track 4:Medical Biotechnology and Biomedical Engineering

Medicine is by means of biotechnology techniques so much in diagnosing and treating dissimilar diseases. It also gives opportunity for the population to defend themselves from hazardous diseases. The pasture of biotechnology, genetic engineering, has introduced techniques like gene therapy, recombinant DNA technologyand polymerase chain retort which employ genes and DNA molecules to make adiagnosis diseasesand put in new and strong genes in the body which put back the injured cells. There are some applications of biotechnology which are live their part in the turf of medicine and giving good results.

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA;Global Biotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & Biotech Patent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkers in Diagnostics, Oct 07-08, 2015 Berlin, Germany, DEU.

Track 5:Agricultural Biotechnology

Biotechnology is being used to address problems in all areas of agricultural production and processing. This includesplant breedingto raise and stabilize yields; to improve resistance to pests, diseases and abiotic stresses such as drought and cold; and to enhance the nutritional content of foods. Modern agricultural biotechnology improves crops in more targeted ways. The best known technique is genetic modification, but the term agricultural biotechnology (or green biotechnology) also covers such techniques asMarker Assisted Breeding, which increases the effectiveness of conventional breeding.

Related Conferences

3rd GlobalFood Safety Conference, September 01-03, 2016, Atlanta USA; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 12thBiotechnology Congress, Nov 14-15, 2016, San Francisco, USA;Biologically Active Compoundsin Food, October 15-16 2015 Lodz, Poland; World Conference onInnovative Animal Nutrition and Feeding, October 15-17, 2015 Budapest, Hungary; 18th International Conference onFood Science and Biotechnology, November 28 - 29, 2016, Istanbul, Turkey; 18th International Conference on Agricultural Science, Biotechnology,Food and Animal Science, January 7 - 8, 2016, Singapore; International IndonesiaSeafood and Meat, 1517 October 2016, Jakarta, Indonesia.

Track 6:Industrial Biotechnology and Pharmaceutical Biotechnology

Industrial biotechnology is the application of biotechnology for industrial purposes, includingindustrial fermentation. The practice of using cells such as micro-organisms, or components of cells like enzymes, to generate industrially useful products in sectors such as chemicals, food and feed, detergents, paper and pulp, textiles andbiofuels. Industrial Biotechnology offers a premier forum bridging basic research and R&D with later-stage commercialization for sustainable bio based industrial and environmental applications.

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA; GlobalBiotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & BiotechPatent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkers in Diagnostics, Oct 07-08, 2015 Berlin, Germany, DEU.

Track 8:Microbial and Biochemical Technology

Microorganisms have been exploited for their specific biochemical and physiological properties from the earliest times for baking, brewing, and food preservation and more recently for producingantibiotics, solvents, amino acids, feed supplements, and chemical feedstuffs. Over time, there has been continuous selection by scientists of special strains ofmicroorganisms, based on their efficiency to perform a desired function. Progress, however, has been slow, often difficult to explain, and hard to repeat. Recent developments inmolecular biologyand genetic engineering could provide novel solutions to long-standing problems. Over the past decade, scientists have developed the techniques to move a gene from one organism to another, based on discoveries of how cells store, duplicate, and transfer genetic information.

Related conferences

3rdGlobal Food Safety Conference, September 01-03, 2016, Atlanta USA; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 12thBiotechnology Congress, Nov 14-15, 2016, San Francisco, USA;Biologically Active Compoundsin Food, October 15-16 2015 Lodz, Poland; World Conference onInnovative Animal Nutrition and Feeding, October 15-17, 2015 Budapest, Hungary; 18th International Conference onFood Science and Biotechnology, November 28 - 29, 2016, Istanbul, Turkey; 18th International Conference on Agricultural Science, Biotechnology,Food and Animal Science, January 7 - 8, 2016, Singapore; International IndonesiaSeafood and Meat, 1517 October 2016, Jakarta, Indonesia.

Track 9:Food Processing and Technology

Food processing is a process by which non-palatable and easily perishable raw materials are converted to edible and potable foods and beverages, which have a longer shelf life. Biotechnology helps in improving the edibility, texture, and storage of the food; in preventing the attack of the food, mainly dairy, by the virus likebacteriophage producing antimicrobial effect to destroy the unwanted microorganisms in food that cause toxicity to prevent the formation and degradation of other toxins andanti-nutritionalelements present naturally in food.

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA;Global Biotechnology Congress 2016, May 11th-14th 2016, Boston, MA, USA;BIO Investor Forum, October 20-21, 2015, San Francisco, USA;BIO Latin America Conference, October 14-16, 2015, Rio de Janeiro, Brazil;Bio Pharm America 20158th Annual International Partnering Conference, September 15-17, 2015, Boston, MA, USA.

Track 10:Genetic Engineering and Molecular Biology

One kind of biotechnology is gene technology, sometimes called 'genetic engineering' or'genetic modification', where the genetic material of living things is deliberately altered to enhance or remove a particular trait and allow the organism to perform new functions. Genes within a species can be modified, or genes can be moved from one species to another. Genetic engineering has applications inmedicine, research, agriculture and can be used on a wide range of plants, animals and microorganisms. It resulted in a series of medical products. The first two commercially prepared products from recombinant DNA technology were insulin andhuman growth hormone, both of which were cultured in the E. coli bacteria.

The field of molecular biology overlaps with biology and chemistry and in particular, genetics and biochemistry. A key area of molecular biology concerns understanding how various cellular systems interact in terms of the way DNA, RNA and protein synthesis function.

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA;Global Biotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & BiotechPatent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkers in Diagnostics, Oct 07-http://world.biotechnologycongress.com/08, 2015 Berlin, Germany, DEU.

Track 11:Tissue Science and Engineering

Tissue engineering is emerging as a significant potential alternative or complementary solution, whereby tissue and organ failure is addressed by implanting natural, synthetic, orsemisynthetic tissueand organ mimics that are fully functional from the start or that grow into the required functionality. Initial efforts have focused on skin equivalents for treating burns, but an increasing number of tissue types are now being engineered, as well as biomaterials and scaffolds used as delivery systems. A variety of approaches are used to coax differentiated or undifferentiated cells, such as stem cells, into the desired cell type. Notable results includetissue-engineeredbone, blood vessels, liver, muscle, and even nerve conduits. As a result of the medical and market potential, there is significant academic and corporate interest in this technology.

Related Conferences

11th World Congress onBiotechnology and Biotech Industries Meet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 13thBiotechnology Congress, Nov 28-30, 2016, San Francisco, USA;Global Biotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA;Biomarker Summit2016, March 21-23, 2016 San Diego, CA, USA; 14thVaccines Research & Development, July 7-8, Boston, USA;Pharmaceutical & BiotechPatent Litigation Forum, Mar 14 - 15, 2016, Amsterdam, Netherlands; 4thBiomarkers in Diagnostics, Oct 07-08, 2015 Berlin, Germany, DEU.

Track 12:Nano Biotechnology

Nano biotechnology, bio nanotechnology, and Nano biology are terms that refer to the intersection of nanotechnology and biology. Bio nanotechnology and Nano biotechnology serve as blanket terms for various related technologies. The most important objectives that are frequently found inNano biologyinvolve applying Nano tools to relevantmedical/biologicalproblems and refining these applications. Developing new tools, such as peptide Nano sheets, for medical and biological purposes is another primary objective in nanotechnology.

Related Conferences

8thWorldMedicalNanotechnologyCongress& Expo during June 9-11, Dallas, USA; 6thGlobal Experts Meeting and Expo onNanomaterialsand Nanotechnology, April 21-23, 2016 ,Dubai, UAE; 12thNanotechnologyProductsExpo, Nov 10-12, 2016 at Melbourne, Australia; 5thInternationalConference onNanotechand Expo, November 16-18, 2015 at San Antonio, USA; 11thInternational Conference and Expo onNano scienceandMolecular Nanotechnology, September 26-28 2016, London, UK; 18thInternational Conference onNanotechnologyand Biotechnology, February 4 - 5, 2016 in Melbourne, Australia; 16thInternational Conference onNanotechnology, August 22-25, 2016 in Sendai, Japan; International Conference onNano scienceand Nanotechnology, 7-11 Feb 2016 in Canberra, Australia; 18thInternational Conference onNano scienceand Nanotechnology, February 15 - 16, 2016 in Istanbul, Turkey; InternationalNanotechnologyConference& Expo, April 4-6, 2016 in Baltimore, USA.

Track 13:Bioinformatics and Biosensors

Bioinformatics is the application of computer technology to the management of biological information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied to gene-based drug discovery and development. The science of Bioinformatics, which is the melding of molecular biology with computer science, is essential to the use of genomic information in understanding human diseases and in the identification of newmolecular targetsfor drug discovery. This interesting field of science has many applications and research areas where it can be applied. It plays an essential role in today's plant science. As the amount of data grows exponentially, there is a parallel growth in the demand for tools and methods indata management, visualization, integration, analysis, modeling, and prediction.

Related conferences

11th World Congress onBiotechnology and Biotech IndustriesMeet, July 28-29, 2016, Berlin, Germany; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, Thailand; 11thEuro Biotechnology Congress, November 07-09,2016, Alicante Spain; 12thBiotechnology Congress, Nov 14-15, 2016, San Francisco, USA;BIO IPCC Conference, Cary, North Carolina, USA; World Congress onIndustrial Biotechnology, April 17-20, 2016, San Diego, CA; 6thBio based Chemicals: Commercialization & Partnering, November 16-17, 2015, San Francisco, CA, USA; The European Forum forIndustrial Biotechnology and Bio economy, 27-29 October 2015, Brussels, Belgium; 4thBiotechnology World Congress, February 15th-18th, 2016, Dubai, United Arab Emirates; International Conference on Advances inBioprocess Engineering and Technology, 20th to 22nd January 2016,Kolkata, India; GlobalBiotechnology Congress2016, May 11th - 14th 2016, Boston, MA, USA

Track 14:Biotechnology investments and Biotech grants

Every new business needs some startup capital, for research, product development and production, permits and licensing and other overhead costs, in addition to what is needed to pay your staff, if you have any. Biotechnology products arise from successfulbiotechcompanies. These companies are built by talented individuals in possession of a scientific breakthrough that is translated into a product or service idea, which is ultimately brought into commercialization. At the heart of this effort is the biotech entrepreneur, who forms the company with a vision they believe will benefit the lives and health of countless individuals. Entrepreneurs start biotechnology companies for various reasons, but creatingrevolutionary productsand tools that impact the lives of potentially millions of people is one of the fundamental reasons why all entrepreneurs start biotechnology companies.

10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok; 11thEuroBiotechnologyCongress, November 7-9, 2016 Alicante, Spain; 11th World Congress onBiotechnology and Biotech IndustriesMeet, July 28-29, 2016, Berlin, Germany; 13thBiotechnologyCongress, November 28-30, 2016 San Francisco, USA; 10thAsia Pacific Biotech CongressJuly 25-27, 2016, Bangkok, UAE;BioInternational Convention, June 6-9, 2016 | San Francisco, CA;BiotechJapan, May 11-13, 2016, Tokyo, Japan;NANO BIOEXPO 2016, Jan. 27 - 29, 2016, Tokyo, Japan;ArabLabExpo2016, March 20-23, Dubai; 14thInternational exhibition for laboratory technology,chemical analysis, biotechnology and diagnostics, 12-14 Apr 2016, Moscow, Russia

Read more here:
Biotechnology Conferences | USA Biotech events ...

The recent performance of Vir Biotechnology (NASDAQ:VIR) stock in the market spoke loud and clear to investors as VIR saw more than 1.13M shares in trading volumes in the last trading session, way higher than the average trading volume of 1.13M shares by far recorded in the movement of Vir Biotechnology (VIR). At the time the stock opened at the value of $29.55, making it a high for the given period, the value of the stock jumped by 3.56%. After the increase, VIR touched a low price of $29.55, calling it a day with a closing price of $30.08, which means that the price of VIR went 1.6 below the opening price on the mentioned day.

Given the most recent momentum in the market in the price movement of VIR stock, some strong opinions on the matter of investing in the companys stock started to take shape, which is how analysts are predicting an estimated price of $34.33 for VIR within consensus. The estimated price would demand a set of gains in total of -37.91%, which goes higher than the most recent closing price, indicating that the stock is in for bullish trends. Other indicators are hinting that the stock could reach an outstanding figure in the market share, which is currently set at 100.45M in the public float and 3.41B US dollars in market capitalization.

When it comes to the technical analysis of VIR stock, there are more than several important indicators on the companys success in the market, one of those being the Relative Strength Indicator (RSI), which can show, just as Stochastic measures, what is going on with the value of the stock beneath the data. This value may also indicate that the stock will go sideways rather than up or down, also indicating that the price could stay where it is for quite some time. When it comes to Stochastic reading, VIR stock are showing 26.08% in results, indicating that the stock is neither overbought or oversold at the moment, providing it with a neutral within Stochastic reading as well. Additionally, VIR with the present state of 200 MA appear to be indicating bullish trends within the movement of the stock in the market. While other metrics within the technical analysis are due to provide an outline into the value of VIR, the general sentiment in the market is inclined toward positive trends.

With the previous 100-day trading volume average of 543315 shares, Pinnacle Financial Partners (PNFP) recorded a trading volume of 717220 shares, as the stock started the trading session at the value of $34.35, in the end touching the price of $34.88 after jumping by 1.54%.

PNFP stock seem to be going ahead the lowest price in the last 52 weeks with the latest change of 25.47%.Then price of PNFP also went backward in oppose to its average movements recorded in the previous 20 days. The price volatility of PNFP stock during the period of the last months recorded 6.96%, whilst it changed for the week, now showing 5.92% of volatility in the last seven days. The trading distance for this period is set at -7.95% and is presently away from its moving average by -22.96% in the last 50 days. During the period of the last 5 days, PNFP stock lost around -2.84% of its value, now recording a dip by -37.07% reaching an average $55.32 in the period of the last 200 days.During the period of the last 12 months, Pinnacle Financial Partners (PNFP) dropped by -45.50%.

According to the Barcharts scale, the companys consensus rating was unchanged to 4.00 from 4.00, showing an overall improvement during the course of a single month. Based on the latest results, analysts are suggesting that the target price for PNFP stock should be $34.88 per share in the course of the next 12 months. To achieve the target price as suggested by analysts, PNFP should have a spike by 0% in oppose to its present value in the market. Additionally, the current price showcases a discount of 34.19% when compared to the high consensus price target predicted by analysts.

PNFP shares recorded a trading volume of 588569 shares, compared to the volume of 638.57K shares before the last close, presented as its trading average. With the approaching 5.92% during the last seven days, the volatility of PNFP stock remained at 6.96%. During the last trading session, the lost value that PNFP stock recorded was set at the price of $34.88, while the lowest value in the last 52 weeks was set at $27.80. The recovery of the stock in the market has notably added 25.47% of gains since its low value, also recording -0.11% in the period of the last 1 month.

Read the original post:
Will These Thrive Or Dive ? Vir Biotechnology (VIR), Pinnacle Financial Partners (PNFP) - US Post News

New Delhi: Department of Biotechnology, Ministry of Science & Technology, today celebrated its 34th Foundation Day at the National Institute of Immunology (NII), New Delhi.

Speaking on the occasion, the Chief Guest, Minister for S&T, Earth Sciences and MoH&FW, Dr. Harsh Vardhan congratulated the Department of Biotechnology for its pioneering work over the years and called upon all scientists to engage themselves in innovative ideas and work to meet new challenges by the time the nation celebrates its 75 years of independence in 2022 to realise the vision of the Prime Minister Shri Narendra Modi of a new India. Dr. Harsh Vardhan also called upon young scientists and awardees to come up with new solutions for the event which he called as India @ 75.

The Minister acknowledged the immense contribution made by former Secretary DBY, Prof. M K Bhan whom we had lost very recently. He announced launching of M K Bhan Young Investigators Research Award in Prof. Bhans memory by DBT to promote young investigators working in challenging areas of research.

Dr. Harsh Vardhan praised the Departments efforts in launching three New National Level Initiatives as a part of the 100 Day Programme:

Launch of Genome India;Biotech KISAN hub in all Aspirational Districts andWaste to value technologies.The Minister also gave away the Awards to 34 recipients on the occasion. Department since its inception has instituted various awards to encourage and recognize the contribution of scientists working in various research institutes, universities, scientific organizations, national laboratories etc at different levels across the country. Various awards instituted by DBT are now considered under an overarching umbrella as DBT BRITE Awards [Biotechnology Research Innovation and Technology Excellence Awards]. The Department has renamed few awards in honour of outstanding scientists of our country who have immensely contributed to the Indian Science and been an inspiration to scientific fraternity across the globe.

DBT BRITE Awards constitutes the following awards hosted by DBT:

Har Gobind Khorana-Innovative Young Biotechnologist AwardS. Ramachandran-National Bioscience Award for Career DevelopmentJanaki Ammal Natioanl Women Bioscientist AwardTata Innovative Fellowship AwardBiotechnology Social Development AwardEminent scientist Padma Shri Dr. D Balasubramaian, Emeritus Director, LV Prasad Eye Institute, Hyderabad delivered the DBT Foundation day lecture.

The Minister also released a publication by the Department Biotechnology- Contributing to Growing Bioeconomy.

The biotechnology sector in India has evolved over the last three decades and has made significant contribution in various sectors especially health, agriculture etc. Due to enormous support received both from government & private sector biotechnology sector has seen a rapid growth amounting to an annual growth rate of nearly 20%. India is rated among top 12 biotechnology destinations in the world.

It is the demand for biotechnology products and services that has been the fulcrum for setting an ambitious target of US$150 billion by 2025. Looking at the growth prospects, biotech sector plays a significant role in addressing major global challenges in sectors like health care, agriculture, energy, live stock etc. Since, our focus is on innovation and R&D, the Foundation Day of DBT is the right occasion to discuss what are the ways and strategies to be implemented to achieve set target or at least reach near the defined goals.

To do so, we need to nurture talent and reward them for their excellence so that they keep working towards nation building.

Read more here:
India rated among top 12 biotechnology destinations in the world - India Education Diary

Low cost of capital has fueled exceptional returns for biotech and health stocks but will near zero cost financing last?

Biotechnology & Healthcare was the top performing investment company sector of the last decade producing a return of 491% from 2010 to 2019, compared to a return of 198% for the average investment company over the same period, according to the Association of Investment Trusts (AIC).

The UK Smaller Companies and Global Smaller Companies sectors were the second and third best performing sectors of the decade and delivered 379% and 330% respectively. European Smaller Companies (10th) also featured in the top ten.

Meanwhile the best performing investment companies over the past decade came from a variety of sectors, but companies in the UK Smaller Companies sector featured most strongly, making four appearances within the top ten.

Volta Finance was the best performing member company over the decade. The company from the Debt Structured Finance sector produced an impressive 959% share price total return from 1 January 2010 to 31 December 2019. It was followed by Lindsell Train in the Global sector, up 730%, and Baillie Gifford Shin Nippon from the Japanese Smaller Companies sector, up 678% over the same period.

Annabel Brodie-Smith, communications director of the AIC said: Its encouraging to see a diverse spectrum of investment company sectors perform so strongly over the last decade. While Biotechnology & Healthcare was the top performing sector by some margin, two UK equity sectors made it into the top ten despite the Brexit referendum and subsequent lack of clarity surrounding the UKs exit.

The closed-ended investment company structure lends itself particularly well to illiquid alternative investments and over the past decade the Private Equity and Infrastructure sectors have both delivered particularly strong returns. Three smaller company sectors feature in the top ten best performers, demonstrating that investment companies are the best vehicle for holding smaller companies which can be hard to sell in times of stress. In addition, investors who have favoured investment companies to gain overseas exposure via the Japan, Global and North America sectors have been handsomely rewarded.

Its always interesting to look back at the best performing companies, but its important to remember that past performance is not an indicator of future returns. Investment companies cover a broad variety of sectors, risk profiles and geographical exposure to match a range of investor needs. When investing you should consider your objectives and the level of risk you are willing to take and, if you have any concerns, you should speak to a financial adviser.

Jason Hollands, managing director, business development and communications at Tilney Investment Management Services said: The last decade has seen huge advances in medical discovery. When combined with an extraordinarily supportive, post global crisis environment for risk assets i.e. low cost of capital thats fueled exceptional returns for biotech and health stocks.

While there is no reason to doubt further advancements in medical science, we wont remain locked in a world of near zero real financing costs forever. Of particular relevance is mounting pressure across the global for greater controls over drug pricing, given the spiraling costs to health services. This could be particularly relevant if the Democrats win the US Presidential election as their nominees have been vocal on this as well as calling for a much more interventionist role for the state in the massive US healthcare market.

With regards to the overall observations below. The broad theme is that smaller companies across a variety of markets have been amongst the best performing parts of the market. Ironically this has taken place over a period during which investors have increasingly shunned them in the clamour for passive products that are overwhelming skewed to large-cap companies. Frankly, the more smaller companies are ignored, the greater the potential available for active managers to add value in this space by spotting winners that the wider market has yet to discover.

Further reading: Investment Trusts: A beginners guide

Link:
Biotechnology and Healthcare is the best performing IT fund sector - What Investment

Biotechnology is the use of biological systems found in organisms or the use of the living organisms themselves to make technological advances and adapt those technologies to various different fields. These include applications in various fields from agricultural practice to the medical sector. It does not only include applications in fields that involve the living, but any other field where the information obtained from the biological aspect of an organism can be applied.

Biotechnology is particularly vital when it comes to the development of miniscule and chemical tools as many on the tools biotechnology uses exist at the cellular level. In a bid to understand more regarding biotechnology, here are its types, examples and its applications.

According to Biotechnology Innovation Organization,

Biotechnology is technology based on biology biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the health of our planet. We have used the biological processes of microorganisms for more than 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

Medical biotechnology is the use of living cells and other cell materials for the purpose of bettering the health of humans. Essentially, it is used for finding cures as well as getting rid of and preventing diseases. The science involved includes the use of these tools for the purpose of research to find different or more efficient ways of maintaining human health, understanding pathogen, and understanding the human cell biology.

Here, the technique is used to produce pharmaceutical drugs as well as other chemicals to combat diseases. It involves the study of bacteria, plant and animal cells to first understand the way they function at a fundamental level.

It heavily involves the study of DNA (Deoxyribonucleic acid) to get to know how to manipulate the genetic makeup of cells to increase the production of beneficial characteristics that humans might find useful such as the production of insulin. The field usually leads to the development of new drugs and treatments, novel to the field.

Vaccines are chemicals that stimulate the bodys immune system to better fight pathogens when they attack the body. They achieve this by inserting attenuated (weakened) versions of the disease into the bodys bloodstream. This causes the body to react as if it was under attack from the non-attenuated version of the disease. The body combats the weakened pathogens and through the process takes note of the cell structure of the pathogens and has some cell remember the disease and store away the information within the body.

When the individual becomes exposed to the actual disease, the body of the individual immediately recognizes it and quickly forms a defense against it since it already has some information on it. This translates to quicker healing and less time being symptomatic.

The attenuated disease pathogens are extracted using biotechnological techniques such as growing the antigenic proteins in genetically engineered crops. An example is the development of an anti-lymphoma vaccine using genetically engineered tobacco plants made to exhibit RNA (A similar chemical to DNA) from malignant (actively cancerous) B-cells.

Strides have been made in the development of antibiotics that combat pathogens for humans. Many plants are grown and genetically engineered to produce the antibodies. The method is more cost effective than using cells or extracting these antibodies from animals as the plants can produce these antibodies in larger quantities.

Agricultural biotechnology focuses on developing genetically modified plants for the purpose of increasing crop yields or introducing characteristics to those plants that provide them with an advantage growing in regions that place some kind of stress factor on the plant namely weather and pests.

In some of the cases, the practice involves scientists identifying a characteristic, finding the gene that causes it, and then putting that gene within another plant so that it gains that desirable characteristic, making it more durable or having it produce larger yields than it previously did.

Biotechnology has provided techniques for the creation of crops that express anti pest characteristics naturally, making them very resistant to pests, as opposed to having to keep dusting them and spraying them with pesticides. An example of this would be the fungus Bacillus thuringiensis genes being transferred to crops.

The reason for this is that the fungus produces a protein (Bt) which is very effective against pests such as the European corn borer. The Bt protein is the desired characteristic scientist would like the plants to have and for this reason, they identified the gene causing Bt protein to express in the fungus and transferred it to corn. The corn then produces the protein toxin naturally, lowering the cost of production by eliminating the cost of dusting the crop with pesticide.

Selective breeding has been a practice humans have engaged in since farming began. The practice involves choosing the animals with the most desirable characteristics to breed with each other so that the resulting offspring would also express these traits. Desirable characteristics included larger animals, animals more resistant to disease and more domicile animals, all geared to making the process of farming as profitable as possible.

This practice has been transferred to the molecular level with the same purpose. Different traits are selected among the animals and once the genetic markers have been pointed out, animals and plants with those traits are selected and bred for those traits to be transferred. A genomic understanding of those traits is what informs the decisions on whether the desired traits will express or get lost as recessive traits which do not express.

This information provides the basis for making informed decisions enhancing the capability of the scientists to predict the expression of those genes. An example is its use in flower production where traits such as color and smell potency are enhanced.

One of the biggest uses of biotechnology is the infusion of nutrients into food in situations such as aid. Therefore, it provides food with heavy nutrients that are necessary in such situations. An example of this application is the production Golden Rice where the rice is infused with beta-carotene. The rice has Vitamin A, which the body can easily synthesise.

There is actually very little land on earth that is arable with some estimates place it at around 20 percent. With an increase in the worlds population, there is a need for the food sources available to be as effective as possible to produce as much food in as little space as possible. There is also need to have the crops grown to be able to make use of the less arable regions of the world.

This means that there is a need to develop crops that can handle these abiotic stresses such as salinity, drought and frost from cold. In Africa and the Middle East, for instance, where the climate can be unforgiving, the practice has played a significant role in the development of crops that can withstand the prevailing harsh climates.

The industrial applications of biotechnology range from the production of cellular structures to the production of biological elements for numerous uses. Examples include the creation of new materials in the construction industry, and the manufacture of beer and wine, washing detergents, and personal care products.

One of the materials with the strongest tensile strength is spider webs. Amongst other materials with the same cross sectional width, spider webs can take more tensional force before breaking than even steel. This silk has created a lot of interest with the possible production of materials made from silk including body armour such as bullet proof jackets. Silk is used because it is stronger than Kevlar (the material most commonly used to make body armour).

Biotechnological techniques have been used to pick the genes found in spiders and their infusion in goats to produce the silk proteins in their milk. With this initiative, it make production easier as goats are much easier to handle compared to spiders and the production of silk via milk also help make the processing and handling much easier compared to handling the actual silk strands.

One of the biggest applications of biotechnology is in the energy production sector. With fears over the dwindling oil resources in the world and their related environmental impacts, there is a need to protect the globes future by finding alternative environmentally friendly fuel sources. Biotechnology is allowing this to happen with advances such as using corn to produce combustible fuel for running car engines. These fuels are good for the environment as they do not produce the greenhouse gases.

Biotechnology is applied in the healthcare sector is the development of pharmaceuticals that have proven problematic to produce though other conventional means because of purity concerns.

A true environmentalist by heart . Founded Conserve Energy Future with the sole motto of providing helpful information related to our rapidly depleting environment. Unless you strongly believe in Elon Musks idea of making Mars as another habitable planet, do remember that there really is no 'Planet B' in this whole universe.

See the original post here:
What is Biotechnology: Types, Examples and Applications ...

By Chris LangeJanuary 3, 2020 11:15 am

Companies in the biotech industry face an incredible amount of risk while getting their drugs to market. A study coming back negative or a candidate not being approved could crush a company. On the other hand, a positive clinical trial, or even an update from the U.S. Food and Drug Administration (FDA), could send shares skyrocketing.

On a company by company basis, this makes investing in biotechs somewhat tricky. However, there is an investment strategy that makes this process much easier.

To mitigate this risk and concern about picking the winners or the losers within the biotech (or any) industry, exchange-traded funds offer a sampling and exposure to this market without an all-or-none risk in any single companys stock. As the saying goes: Theres an ETF for that strategy. ETF Database has collected much of the information about these ETFs, among others, and made it easily accessible for those looking to get into the game. Investors can use a number of ETFs to invest in a risky biotech industry.

iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) has been around since February 2001, and it aims to track the Nasdaq Biotechnology Index. This fund seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the Nasdaq. Note that this is the largest biotech ETF, with $7.59 billion in assets under management. Its overall expense ratio is 0.47%, and it posted gains of over 22% in 2019. This ETF has a total of 218 holdings. The top 10 holdings include a mix of large-cap domestic biotech companies:

SPDR S&P Biotech ETF (NYSEARCA: XBI) has been around since February 2006 and aims to track the S&P Biotechnology Select Industry Index. This fund seeks to provide exposure to the biotechnology segment of the S&P. It has $4.37 billion in assets under management. Its overall expense ratio is 0.35%, and it traded up 30% over the course of 2019. This fund has 127 holdings. The top 10 holdings include a smattering of U.S. biotechs in the S&P 500:

First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA: FBT) has been around since June 2006 and aims to track the NYSE Arca Biotechnology Index. The fund targets biopharma companies involved with recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology and genomics. It has $1.81 billion in assets under management, its overall expense ratio is 0.57% and it gained over 19% in 2019. This ETF has 31 holdings. The top 10 include mostly domestic biopharma firms:

VanEck Vectors Biotech ETF (NASDAQ: BBH) has been around since December 2011, and it aims to track the MVIS US Listed Biotech 25 Index. This ETF seeks to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It was last seen to have $362.6 million in assets under management. Its overall expense ratio is 0.35%, and it traded up nearly 26% in 2019. This fund has a total of 25 holdings. The top 10 holdings include mostly domestic biotech firms:

By Chris Lange

Excerpt from:
The Top Biotech ETFs to Watch in 2020 - 24/7 Wall St.

About the conference

Biotechnology International Conferences invites all the participants from all over the world to attend 4thInternational Conference onAdvances in Biotechnology and Bioscience during November 15-17, 2018 in Berlin, Germany which includes prompt keynote presentations, Oral Talks, Poster Presentations, Exhibitions.

Biotechnologyis a field which interrelates biological sciences with engineering technologies to increase living organisms and biological systems to produce products . We bring together a diversity of disciplines that complement one another to unravel the complexity of biology. We incorporate the physical sciences, engineering, mathematics, computational and bioinformatics, and the social sciences, as appropriate, to problems we are addressing. We work with animals, plants and microorganisms and our research span the levels of the biological hierarchy from molecules to ecosystems.Bioscienceis defined as technologies that relate to therapeutic or diagnostic products or services, including medical devices and digital health technologies that improve human health. Also included in the state definition are technologies that rely on research to improve agricultural output. As name Bioscience reflects a belief that the study of biological systems is best approached by incorporating many perspectives.

Biotechnology International organizeconferences of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in the USA, Europe & Asia with support from 1000 more scientificsocietiesand publishes 700+Open access journalswhich contains over 30000 eminent personalities, reputed scientists as editorial board members.

Why to attend???

This unique international conference provides a platform for researchers and decision makers in Biotechnology and Bioscience to present their latest findings and learn about all the important developments in Biotechnology and Bioscience. Many scientists and world's renowned experts will participate in the conference. Throughout the course of the two-day conference, you will have the opportunity to both networks and hear leaders from the international academic and corporate bioscience communities.

Target Audience:

The conference will attract a large group of scientists and researchers from around the globe. Delegates will have a valuable, informative and positive experience.

Track: Biotechnology

Biotechnologyis the usage of living systems and organisms to develop or make products, mark or modify products or processes for specific use". Science and innovation have in the past presumed an indispensable part in enhancing general wellbeing.Biotechnology has noteworthy applications in therapeutics, diagnostics, genetically modified crops for agriculture, processed food, bioremediation, waste treatment, and energy production. Biotechnology has likewise prompted to the advancement of anti-infection agents.

Related Biotechnology Conferences | Genetic Engineering Conferences | Pharmaceutical Chemistry Conferences | Biological Engineering Conferences | Bio economy Conferences | Biomedicine Conferences | Microbiology Conferences | Molecular Biology Conferences | Nano-Biotechnology Conferences | Biology Conferences | Embryology Conferences | Pharmacogenomics Conferences

21st European Biotechnology Congress, October 11-13, 2018 Moscow, Russia; 22nd Global Biotechnology Congress September 10-11, 2018 Stockholm, Sweden; 4th Synthetic Biology Conferences October 18-19, 2018 Rome, Italy; 4th Tissue Engineering Conferences; October 18-19, 2018 Rome, Italy; 11th Tissue Engineering Conferences October 18-20, 2018 Rome, Italy; 11th Regenerative Medicine Conferences October 18-20, 2018 at Rome, Italy; The 2nd edition of Biotech France 2018 International Conference and Exhibition June 27 -29, 2018 Paris, France; BIO World Congress on Industrial Biotechnology July 16 - 19, 2018 Philadelphia, Pennsylvania; World Biotechnology Conference June 25-27, 2018 Stockholm, Sweden; International Biotechnology and Research Conference April 25-27, 2018 Rome, Italy

Related Societies:

Europe: Spanish Society of Biotechnology, The Pharmaceutical Society of Ireland, Russian Medical Society, Society for Engineering in Agriculture, Society of Microbial Ecology and Disease, Manchester University Pharmaceutical Society, Italian Society of Biochemistry and Molecular Biology, European Society for Precision Engineering and Nanotechnology, Society for Chemical Engineering Biotechnology, Romanian Society of Medical Mycology and Mycotoxicology, New Zealand Plant Protection Society, International Society for Pharmaceutical Engineering, Pharmaceutical Society of Australia.

Related Societies:

Related Societies:

Related Societies:

Related Societies:

Related Societies:

Related Biotechnology Conferences | Genetic Engineering Conferences | Pharmaceutical Chemistry Conferences | Biological Engineering Conferences | Bio economy Conferences | Biomedicine Conferences | Microbiology Conferences | Molecular Biology Conferences | Nano-Biotechnology Conferences | Biology Conferences | Embryology Conferences | Pharmacogenomics Conferences

4th Glycobiology World Congress September 17-19, 2018 Rome, Italy; 13th Metabolomics Conferences October 11-12, 2018 Zurich, Switzerland; 13th Systems Biology Conferences October 11-12, 2018 Zurich, Switzerland; 14th Structural Biology Conferences September 24-26, 2018 Berlin, Germany; 12th Bioinformatics Conferences November 26-27, 2018 Dublin, Ireland; 12th Drug Discovery Conferences November 26-27, 2018 Dublin, Ireland; 12th Proteomics Expo November 26-28, 2018 Dublin, Ireland; 12th Molecular Medicine November 26-28, 2018 Dublin, Ireland; 5th Enzymology Conferences February 28-March 01, 2019 Berlin, Germany; Biomanufacturing Strategy Meeting June 11, 2018 Boston, United States; Biostimulants Summit 2018 June 27-28, 2018 Chicago, United States; European Microbiology and Research Conference July 04-06, 2018 Rome, Italy; Molecular Diagnostics July 09-10, 2018; London, UK; 18th International Biotechnology Symposium and Exhibition August 12-17, 2018 Montral, Canada; International Conference On Nanomedicine And Nanobiotechnology September26-28, 2018 Rome, Italy; Marine Biotechnology October 08-12, 2018 Naples, Italy; 2nd International Probiotics, Nutrition & Microbiome Conference October 10-12, 2018 Amsterdam, Netherlands

Related Societies:

Related Biotechnology Conferences | Genetic Engineering Conferences | Pharmaceutical Chemistry Conferences | Biological Engineering Conferences | Bio economy Conferences | Biomedicine Conferences | Microbiology Conferences | Molecular Biology Conferences | Nano-Biotechnology Conferences | Biology Conferences | Embryology Conferences | Pharmacogenomics Conferences

4th Synthetic Biology Conferences October 18-19, 2018 Rome, Italy; 4th Tissue Engineering Conferences; October 18-19, 2018 Rome, Italy; 11th Tissue Engineering Conferences October 18-20, 2018 Rome, Italy; 11th Regenerative Medicine Conferences October 18-20, 2018 at Rome, Italy; 10th Stem Cell Conferences October 08-09, 2018 Zurich, Switzerland; 10th Regenerative Medicine Conferences October 08-09, 2018 Zurich, Switzerland; 9th Cell Conferences March 21-23, 2019 Rome, Italy; 9th Gene Therapy Exhibitions March 21-23, 2019 Rome, Italy; 4th Glycobiology World Congress September 17-19, 2018 Rome, Italy; 13th Metabolomics Conferences October 11-12, 2018 Zurich, Switzerland; 13th Systems Biology Conferences October 11-12, 2018 Zurich, Switzerland; BIO World Congress on Industrial Biotechnology July 16 - 19, 2018 Philadelphia, Pennsylvania; World Biotechnology Conference June 25-27, 2018 Stockholm, Sweden; International Biotechnology and Research Conference April 25-27, 2018 Rome, Italy; 2nd World Congress and Expo on Biotechnology and Bioengineering June 25-27, 2018, Dubai, UAE; BIO Asia International Conference March 5 - 6, 2019 Tokyo, Japan; BIO Patient and Health Advocacy Summit October 25 - 26, 2018 Washington, DC

Related Societies:

Related Societies:

Related Societies:

Read more:
Biotechnology Conferences | Biotechnology Congress | 2018 ...

As if the stress of senior year isnt enough of a headache, Michael Vega began his final chapter of high school with a serious concussion.

A soccer injury in May 2016 had mandated three months recovery time, stealing a summer of soccer training from the North Forsyth graduate.

It hit me hard that I couldnt play, coming in with a big concussion, said Vega, a two-time all-conference award recipient. I had to jump right back into it.

Vega, 17, was cleared to play in the final round of the Forsyth Cup last year, helping his team secure a victory in the championship round for the second year in a row, making school history.

Vega, who spent three years on the varsity team, said one of his favorite high school moments was scoring the conference-winning goal against Asheboro High School as a sophomore.

It was a great experience; theres nothing like it, said Vega, who plays goalie and center back. I knew half the guys from growing up, so its hard to say good-bye.

While Vega said he will not play soccer in college, he will continue playing with the Hispanic League.

Graduation is bittersweet, but Vega said he is glad to have AP Biology and AP Chemistry behind him and is applying to Forsyth Tech to study biotechnology.

Ive learned to surround myself with the right people and never give up, Vega said. Im excited for graduation.

See more here:
North Forsyth grad plans to study biotechnology - Winston-Salem Journal